<DOC>
	<DOCNO>NCT01650649</DOCNO>
	<brief_summary>The primary objective study ass QTc ( interval heart rhythm ) interaction effect lofexidine methadone . The secondary objective study evaluate safety tolerability lofexidine evaluate monitoring pharmacokinetics ( amount drug blood ) , vital sign ( heart rate blood pressure ) adverse event ( side effect ) co-administered methadone ; describe effect opiate withdrawal lofexidine introduce follow 50 % methadone dose reduction , require elicit withdrawal response ; evaluate QTc interaction effect lofexidine compare placebo . The investigator hypothesize agent ( lofexidine methadone ) know prolong QTc interval , combination drug create additive effect create significant safety concern . The investigator hypothesize subject able tolerate therapeutic dose lofexidine ( 0.8 mg four time daily ) methadone maintenance dose lower elicit withdrawal .</brief_summary>
	<brief_title>Main Study Lofexidine Methadone Pharmacodynamic Interaction Methadone Maintained Patients</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled multiple ascend dose study assess safety , tolerability , electrocardiographic effect lofexidine 24 methadone-maintained adult subject . The study include Screening Visit , Inpatient Treatment Visit , Follow-Up Visit . Subjects randomize 3:1 ratio receive 4 tablet lofexidine ( 0.2 mg/tablet ) QID 4 tablet match placebo QID . Subjects stable dose methadone ( 80 - 120 mg/day ) satisfy inclusion exclusion criterion eligible study . Within 21 day Screening Visit , subject report inpatient study facility begin Inpatient Treatment Visit last approximately 11 21 day . This visit include inpatient check-in ( 1 day ) , Methadone Baseline ( 1 day ) , Initial Lofexidine Titration ( 3 5 day ) , 1 2 Lofexidine Plateaus ( 2 4 day ) , Methadone Reduction ( 2 6 day ) Methadone Re-Titration Discharge ( 2 4 day ) . The order step subject proceed Inpatient Treatment Visit vary depend whether subject able titrate high dose lofexidine placebo Initial Lofexidine Titration . The high dose lofexidine ( placebo ) 4 tablet QID ( 0.2 mg lofexidine per tablet placebo ) total daily lofexidine dose 16 tablet ( 3.2 mg placebo ) . Diagrams two scenario occur lofexidine titration locate Figure 1 2 body protocol . During Methadone Baseline phase subject take single daily dose methadone 1 PM undergo baseline study assessment include electrocardiogram ( ECG ) monitoring , blood collection methadone pharmacokinetics , opiate withdrawal assessment ( Clinical Opiate Withdrawal Scale , COWS Short Opiate Withdrawal Scale , SOWS ) . The next day subject proceed Initial Lofexidine Titration phase . Subjects continue use baseline methadone dose . Lofexidine initiate 2 tablet ( 0.4 mg placebo ) QID titrate daily increment single tablet ( 0.2 mg placebo ) QID total daily dose 0.8 mg QID ( placebo ) , tolerate subject . Lofexidine dose escalate daily unless point subject meet protocol-defined dose hold criterion ( describe ) , trigger reduction dose previous high tolerate dose ( 1 tablet dose , 0.2 mg placebo , subject tolerate initial 2 tablet ) . Once subject titrate high dose ( ie , 4 tablet QID ) high tolerate dose determine , proceed 2-day Lofexidine Plateau phase continue receive methadone maintenance dose . If subject unable titrate 4 tablet QID ( 0.8 mg placebo ) , subject continue receive high tolerate dose equal increment ( eg , 2 3 tablet QID 8AM , 1PM , 6PM , 11PM ) day plateau . If subject tolerate 4 tablet QID ( 0.8 mg placebo ) , first day receive 4 tablet QID ( 0.8 mg placebo ) accord normal dosing schedule . On second day , lofexidine dosing schedule modify subject receive 1 tablet ( ie , 0.2 mg placebo ) increase 1 PM lofexidine dose ( 5 tablet : 1 mg placebo ) 1 tablet ( 0.2 mg placebo ) reduction subsequent lofexidine dose ( 3 tablet : 0.6 mg placebo ) 2 dos 4 tablet ( 0.8 mg placebo ) total daily dose 16 tablet ( 3.2 mg/day placebo ) . On second day Lofexidine Plateau phase , subject undergo electrocardiogram ( ECG ) monitoring blood collection methadone lofexidine pharmacokinetics . COWS SOWS assessment perform day Lofexidine Plateau . Subjects titrate daily dose 4 tablet ( 0.8 mg placebo ) QID receive full dose methadone undergo 4-day methadone dose reduction 50 % continue take lofexidine placebo daily dose 16 tablet evaluate effect lofexidine methadone withdrawal sign symptom . These subject complete initial Lofexidine Plateau dose 0.8 mg lofexidine ( placebo ) QID reach COWS 5 great prior fourth day reduce methadone dose administration may proceed early Methadone Re-titration Discharge Investigator 's discretion . If COWS score reach 5 within 4 day , subject proceed Methadone Re-titration Discharge . Subjects unable titrate high lofexidine dose ( 4 tablet : 0.8 mg placebo QID ) receive full dose methadone undergo methadone dose reduction 50 % 6 day continue receive high tolerate dose lofexidine initial titration . On fourth day ( earlier investigator 's discretion base withdrawal response ) , lofexidine titration resume add incremental 1 tablet ( 0.2 mg placebo ) QID previously establish tolerate dose maximum 4 tablet ( 0.8 mg placebo ) QID dose . During subsequent titration attempt lofexidine ( placebo ) dose escalate daily begin fourth day reduction ( earlier base discretion investigator ) unless event subject meet protocol define dose-hold criterion ( describe ) , trigger reduction dose previous high tolerate dose require Lofexidine Plateau procedures describe repeated maintain subject newly reduce methadone dose ( eg , 50 % maintenance dose ) . Subjects unable titrate high lofexidine dose 50 % Methadone Reduction dose titrate Initial Lofexidine Titration repeat Lofexidine Plateau procedure . During Methadone Reduction ( whether subject enter experimental 4-day 50 % withdrawal phase tolerate 4 tablet [ 0.8 mg placebo ] QID lofexidine dose subject continue lofexidine titration 50 % methadone reduction ) , COWS SOWS assessment opiate withdrawal perform . Following completion Lofexidine Plateau ( repeat necessary ) Methadone Reduction , subject begin Methadone Re-Titration Discharge phase lofexidine placebo discontinue methadone re-titrated start dose ( high low dose relative baseline medically indicate discretion investigator ) . Lofexidine may use treat withdrawal symptom , necessary . Following successful methadone titration completion study assessment , subject discharge inpatient study clinic . Subjects return study clinic follow-up visit 7 day ( ±2 day ) follow clinic discharge safety follow-up adverse event collection . Subjects discharge study time unless medically unstable dose methadone . Subject may medically follow regular interval , determine investigator , subject consider sufficiently stable study discharge . Subjects withdraw consent meet one follow study termination criterion prior completion study withdrawn . Study termination criterion apply pre-dose reading . Baseline value vital sign ECG reading refer value obtain time subject admit clinic . 1 . Cardiovascular event include follow : 1 . Systolic blood pressure ( SBP ) &lt; 70 mmHg &gt; 20 % baseline value ( subject asymptomatic , SBP termination criterion &lt; 70 mmHg ) * 2 . Diastolic blood pressure ( DBP ) &lt; 40 mmHg &gt; 20 % baseline value ( subject asymptomatic , DBP termination criterion &lt; 30 mmHg ) * 3 . Heart rate &lt; 40 bpm &gt; 20 % baseline value ( subject asymptomatic , HR termination criterion &lt; 30 bpm ) * 4 . QTc &gt; 500 msec &gt; 25 % baseline value males females* 5 . Absolute QTcF &gt; 500 m female &gt; 480 m male concurrent increase average QTcF value &gt; 60 m baseline value 6 . Persistent increase QTcF &gt; 60 m baseline persistent QTcF≥480 m ≤500 m electrolytes normal 7 . Absolute QRS &gt; 120 m along 25 % increase baseline 8 . Absolute PR &gt; 240 m along 25 % increase baseline 9 . Syncope 10 . Clinically significant arrhythmia ( include telemetry indication ventricular tachycardia , ventricular fibrillation , Torsade de Pointes , 2nd degree AV block ) * *ECGs vital sign may repeat appropriate confirm value rule extraneous result . 2 . Serious medical problem think relate unrelated study medication . 3 . Intercurrent illness medical complication , opinion site investigator , preclude safe administration study medication . At time termination study , subject discontinue lofexidine placebo ; however , may remain inpatient 4 day methadone maintenance dose re-titrated pre-study maintenance dose .</detailed_description>
	<mesh_term>Substance Withdrawal Syndrome</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<mesh_term>Clonidine</mesh_term>
	<mesh_term>Lofexidine</mesh_term>
	<criteria>1 . Adult male and/or female , 18 60 year age ( inclusive ) . 2 . Receiving methadone maintenance treatment opioid dependence stable oncedaily dose 80120 mg least 4 week prior checkin Inpatient Treatment Visit . 3 . Body mass index ≥ 18 ≤ 35 ( kg/m2 ) . 4 . Normal screen result abnormal result deem Investigator clinically insignificant . 5 . Able understand willing sign inform consent form ( ICF ) . 6 . Females practice adequate birth control nonchildbearing potential . Medically acceptable birth control method study include intrauterine device ( IUD ) ; vasectomize partner ( minimum 6 month ) ; postmenopausal ( least 2 year ) ; surgically sterile ( least 6 month ) ; double barrier ( diaphragm spermicide , condom vaginal spermicide ) ; abstinence ; implant intrauterine hormonal contraceptive use least 6 consecutive month prior study dose throughout study duration ; oral , patch inject hormonal contraceptive vaginal hormonal device ( ie , NuvaRing® ) use least 3 consecutive month prior study dose throughout study duration . 1 . Abnormal cardiovascular exam screen randomization , include follow : clinically significant abnormal electrocardiogram ( ECG ) ( eg , significant first degree atrioventricular block , complete leave bundle branch block [ LBBB ] , second third degree heart block , clinically significant arrhythmia , QTc interval ( machine read ) great 450 msec male great 470 msec female ) * heart rate &lt; 55 bpm symptomatic bradycardia* systolic blood pressure ( SBP ) &lt; 95 mmHg symptomatic hypotension* diastolic blood pressure ( DBP ) &lt; 65 mmHg* blood pressure ( BP ) &gt; 155/95 mmHg* change orthostatic SBP , DBP , heart rate &gt; 25 % sit value prior history myocardial infarction ( MI ) evidence prior MI ECG* history long QT syndrome relative condition history syncopal episode intraventricular conduction delay QRS duration &gt; 120 ms evidence ventricular preexcitation ( eg , Wolff Parkinson White syndrome ) *ECGs vitals may repeat appropriate order confirm value rule extraneous result . 2 . History presence significant clinically unstable cardiovascular ( include atrial fibrillation , congestive heart failure , myocardial ischemia , indwell pacemaker ) , hepatic , renal , hematological , gastrointestinal , endocrine , immunologic , psychiatric , neurologic , dermatologic disease . 3 . History presence degree chronic obstructive pulmonary disease . 4 . History suicidal ideation depression require professional intervention include counsel antidepressant medication past 12 month . 5 . Positive drug ( urine ) /alcohol ( breath ) test screen checkin exclude methadone . Subjects positive test heroin benzodiazepine Screening Visit may enrol test negative checkin Inpatient Treatment Visit . Subjects positive test heroin benzodiazepine Screening Visit must sign ICF checkin Inpatient Clinic Visit . 6 . Receiving methadone pain management . 7 . Positive test human immunodeficiency virus ( HIV ) hepatitis B surface antigen ( HBsAg ) . Subjects positive test hepatitis C antibody ( HCV ) may enrol subject asymptomatic . 8 . Estimated creatinine clearance &lt; 80 mL/minute screening ( CockcroftGault formula ) . 9 . AST , ALT , alkaline phosphatase &gt; 3.0 x upper limit normal screen checkin . 10 . Amylase lipase &gt; 1.5 x upper limit normal screen checkin . 11 . Clinically significant outofreference range clinical chemistry value , particular attention potassium , magnesium , calcium . 12 . History hypotension . 13 . History hypersensitivity allergy clonidine clonidine analogue . 14 . Use new prescription medication within 12 day prior checkin . 15 . Use overthecounter medication , include herbal product , within 5 day prior checkin . Up 2 gram per day acetaminophen allow discretion principal investigator designee . 16 . Use drug know affect QTc within 30 day prior checkin ( tobacco methadone exclude ) . 17 . Blood donation significant blood loss within 30 day prior checkin . 18 . Plasma donation within 7 day prior checkin . 19 . Participation another clinical trial within 30 day prior checkin . 20 . Females pregnant lactating . 21 . Participation lofexidine hydrochloride pilot protocol USWMLX110051 . 22 . Any condition prior therapy , , opinion Investigator , would make subject unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>lofexidine</keyword>
	<keyword>methadone</keyword>
	<keyword>interaction</keyword>
	<keyword>pharmacodynamic</keyword>
	<keyword>ECG</keyword>
	<keyword>QTc</keyword>
</DOC>